CING
Cingulate Inc
NASDAQ · Pharmaceuticals
$7.70
+1.21 (+18.64%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 8.37M | 8.17M | 9.32M |
| Net Income | 2.92M | 2.10M | 3.15M |
| EPS | — | — | — |
| Profit Margin | 34.9% | 25.8% | 33.8% |
| Rev Growth | +14.6% | -6.6% | +11.6% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 15.91M | 14.41M | 17.02M |
| Total Equity | 42.82M | 44.50M | 41.57M |
| D/E Ratio | 0.37 | 0.32 | 0.41 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 4.25M | 3.98M | 4.18M |
| Free Cash Flow | 2.06M | 2.44M | 3.61M |